Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates

Applied and Environmental Microbiology

Volumn 79, Issue 23, 2013, Pages 7142-7149

  Amoureux, Lucie ^a   Bador, Julien ^a   Fardeheb, Sakina ^a   Mabille, Cédric ^a   Couchot, Charlyne ^a   Massip, Clémence ^a   Salignon, Anne Lise ^a   Berlie, Guillaume ^a   Varin, Véronique ^a   Neuwirth, Catherine ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL ISOLATES; ENVIRONMENTAL RESERVOIRS; ENVIRONMENTAL SAMPLE; HEALTHY VOLUNTEERS; HOSPITAL ENVIRONMENT; OUTDOOR ENVIRONMENT; POTENTIAL RESERVOIR; PULSED FIELD GEL ELECTROPHORESIS;

ANTIBIOTICS; ELECTROPHORESIS; RESERVOIRS (WATER);

HOSPITALS;

BACTERIUM; ELECTROKINESIS; FERMENTATION; HOSPITAL SECTOR; IDENTIFICATION METHOD; OXIC CONDITIONS; PATHOGEN;

BOURGOGNE; COTE D'OR; DIJON; FRANCE;

BACTERIAL DNA; BETA LACTAMASE;

ACHROMOBACTER DENITRIFICANS; ARTICLE; CHEMISTRY; CLASSIFICATION; DEMOGRAPHY; DNA SEQUENCE; DRUG EFFECT; FRANCE; GENETIC VARIABILITY; GENETICS; GRAM NEGATIVE INFECTION; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR GENETICS; MOLECULAR TYPING; NUCLEOTIDE SEQUENCE; PULSED FIELD GEL ELECTROPHORESIS;

ACHROMOBACTER DENITRIFICANS; BETA-LACTAMASES; DNA, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; ENVIRONMENTAL MICROBIOLOGY; FRANCE; GENETIC VARIATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MOLECULAR TYPING; RESIDENCE CHARACTERISTICS; SEQUENCE ANALYSIS, DNA;

EID: 84888251176     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.02293-13     Document Type: Article

References (46)

1. Ciofu O, Hansen CR, Hoiby N. 2013. Respiratory bacterial infections in cystic fibrosis. Curr. Opin. Pulm. Med. 19:251-258.
2. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. 2009. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 136:1554-1560.
3. Salvatore D, Buzzetti R, Baldo E, Furnari ML, Lucidi V, Manunza D, Marinelli I, Messore B, Neri AS, Raia V, Mastella G. 2012. An overview of international literature from cystic fibrosis registrie. Part 4: update 2011. J. Cyst. Fibros. 11:480-493.
4. Waters V. 2012. New treatments for emerging cystic fibrosis pathogens other than Pseudomonas. Curr. Pharm. Des. 18:696-725.
5. Hogardt M, Ulrich J, Riehn-Kopp H, Tummler B. 2009. EuroCareCF quality assessment of diagnostic microbiology of cystic fibrosis isolates. J. Clin. Microbiol. 47:3435-3438.
6. Kidd TJ, Ramsay KA, Hu H, Bye PT, Elkins MR, Grimwood K, Harbour C, Marks GB, Nissen MD, Robinson PJ, Rose BR, Sloots TP, Wainwright CE, Bell SC. 2009. Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients. J. Clin. Microbiol. 47:1503-1509.
7. Ahmed MS, Nistal C, Jayan R, Kuduvalli M, Anijeet HK. 2009. Achromobacter xylosoxidans, an emerging pathogen in catheter-related infection in dialysis population causing prosthetic valve endocarditis: a case report and review of literature. Clin. Nephrol. 71:350-354.
8. Aisenberg G, Rolston KV, Safdar A. 2004. Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003). Cancer 101:2134-2140.
9. Tena D, Gonzalez-Praetorius A, Perez-Balsalobre M, Sancho O, Bisquert J. 2008. Urinary tract infection due to Achromobacter xylosoxidans: report of 9 cases. Scand. J. Infect. Dis. 40:84-87.
10. Turel O, Kavuncuoglu S, Hosaf E, Ozbek S, Aldemir E, Uygur T, Hatipoglu N, Siraneci R. 2013. Bacteremia due to Achromobacter xylosoxidans in neonates: clinical features and outcome. Braz. J. Infect. Dis. 17:450-454.
11. Bador J, Amoureux L, Blanc E, Neuwirth C. 2013. Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump. Antimicrob. Agents Chemother. 57:603-605.
12. Bador J, Amoureux L, Duez JM, Drabowicz A, Siebor E, Llanes C, Neuwirth C. 2011. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM. Antimicrob. Agents Chemother. 55:4912-4914.
13. Amoureux L, Bador J, Siebor E, Taillefumier N, Fanton A, Neuwirth C. 2013. Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data. J. Cyst. Fibros. 12:170-176.
14. Lambiase A, Catania MR, Del Pezzo M, Rossano F, Terlizzi V, Sepe A, Raia V. 2011. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 30:973-980.
15. De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. 2007. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J. Cyst. Fibros. 6:75-78.
16. Pereira RH, Carvalho-Assef AP, Albano RM, Folescu TW, Jones MC, Leao RS, Marques EA. 2011. Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patients. J. Clin. Microbiol. 49:3649-3651.
17. Molina-Cabrillana J, Santana-Reyes C, Gonzalez-Garcia A, Bordes-Benitez A, Horcajada I. 2007. Outbreak of Achromobacter xylosoxidans pseudobacteremia in a neonatal care unit related to contaminated chlorhexidine solution. Eur. J. Clin. Microbiol. Infect. Dis. 26:435-437.
18. Olshtain-Pops K, Block C, Temper V, Hidalgo-Grass C, Gross I, Moses AE, Gofrit ON, Benenson S. 2011. An outbreak of Achromobacter xylosoxidans associated with ultrasound gel used during transrectal ultrasound guided prostate biopsy. J. Urol. 185:144-147.
19. Ho YN, Mathew DC, Hsiao SC, Shih CH, Chien MF, Chiang HM, Huang CC. 2012. Selection and application of endophytic bacterium Achromobacter xylosoxidans strain F3B for improving phytoremediation of phenolic pollutants. J. Hazard Mater. 219-220:43-49.
20. Jha P, Kumar A. 2009. Characterization of novel plant growth promoting endophytic bacterium Achromobacter xylosoxidans from wheat plant. Microb. Ecol. 58:179-188.
21. Buckova M, Godocikova J, Zamocky M, Polek B. 2010. Screening of bacterial isolates from polluted soils exhibiting catalase and peroxidase activity and diversity of their responses to oxidative stress. Curr. Microbiol. 61:241-247.
22. Singh NS, Singh DK. 2011. Biodegradation of endosulfan and endosulfan sulfate by Achromobacter xylosoxidans strain C8B in broth medium. Biodegradation 22:845-857.
23. Holmes B, Snell JJ, Lapage SP. 1977. Strains of Achromobacter xylosoxidans from clinical material. J. Clin. Pathol. 30:595-601.
24. Brusse HJ, Auling G. 2005. Genus II. Achromobacter Yabuuchi and Yano 1981, 477VP emend. Yabuuchi, Kawamura, Kosako and Ezaki 1998a, 1083, p 658-662. In Brenner DJ, Krieg NR, Staley JT, GarrityGM(ed), Bergey's manual of systematic bacteriology, 2nd ed, vol 2, part C. Springer, New York, NY.
25. Wirsing von Konig CH RM, Coenye T. 2011. Bordetella and related genera, p 739-750. In Versalovic J CK, Jorgensen JH, Funke G, Landry ML, Warnock DW (ed), Manual of clinical microbiology, 10th ed, vol 1. ASM Press, Washington, DC.
26. Spear JB, Fuhrer J, Kirby BD. 1988. Achromobacter xylosoxidans (Alcaligenes xylosoxidans subsp. xylosoxidans) bacteremia associated with a wellwater source: case report and review of the literature. J. Clin. Microbiol. 26:598-599.
27. Degand N, Carbonnelle E, Dauphin B, Beretti JL, Le Bourgeois M, Sermet-Gaudelus I, Segonds C, Berche P, Nassif X, Ferroni A. 2008. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of nonfermenting gram-negative bacilli isolated from cystic fibrosis patients. J. Clin. Microbiol. 46:3361-3367.
28. Desai AP, Stanley T, Atuan M, McKey J, Lipuma JJ, Rogers B, Jerris R. 2012. Use of matrix assisted laser desorption ionisation-time of flight mass spectrometry in a paediatric clinical laboratory for identification of bacteria commonly isolated from cystic fibrosis patients. J. Clin. Pathol. 65:835-838.
29. Marko DC, Saffert RT, Cunningham SA, Hyman J, Walsh J, Arbefeville S, Howard W, Pruessner J, Safwat N, Cockerill FR, Bossler AD, Patel R, Richter SS. 2012. Evaluation of the Bruker Biotyper and Vitek MS matrixassisted laser desorption ionization-time of flight mass spectrometry systems for identification of nonfermenting gram-negative bacilli isolated from cultures from cystic fibrosis patients. J. Clin. Microbiol. 50:2034-2039.
30. Doi Y, Poirel L, Paterson DL, Nordmann P. 2008. Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans. Antimicrob. Agents Chemother. 52:1952-1956.
31. Turton JF, Mustafa N, Shah J, Hampton CV, Pike R, Kenna DT. 2011. Identification of Achromobacter xylosoxidans by detection of the blaOXA-114-like gene intrinsic in this species. Diagn. Microbiol. Infect. Dis. 70:408-411.
32. Cheron M, Abachin E, Guerot E, El-Bez M, Simonet M. 1994. Investigation of hospital-acquired infections due to Alcaligenes denitrificans subsp. xylosoxydans by DNA restriction fragment length polymorphism. J. Clin. Microbiol. 32:1023-1026.
33. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
34. Barrado L, Branas P, Orellana MA, Martinez MT, Garcia G, Otero JR, Chaves F. 2013. Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain. J. Clin. Microbiol. 51:1927-1930.
35. Siebor E, Llanes C, Lafon I, Ogier-Desserrey A, Duez JM, Pechinot A, Caillot D, Grandjean M, Sixt N, Neuwirth C. 2007. Presumed pseudo-bacteremia outbreak resulting from contamination of proportional disinfectant dispenser. Eur. J. Clin. Microbiol. Infect. Dis. 26:195-198.
36. Moissenet D, Baculard A, Valcin M, Marchand V, Tournier G, Garbarg-Chenon A, Vu-Thien H. 1997. Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation. Clin. Infect. Dis. 24:274-275.
37. Ridderberg W, Wang M, Norskov-Lauritsen N. 2012. Multilocus sequence analysis of isolates of Achromobacter from patients with cystic fibrosis reveals infecting species other than Achromobacter xylosoxidans. J. Clin. Microbiol. 50:2688-2694.
38. Spilker T, Vandamme P, Lipuma JJ. 2012. A multilocus sequence typing scheme implies population structure and reveals several putative novel Achromobacter species. J. Clin. Microbiol. 50:3010-3015.
39. Hota S, Hirji Z, Stockton K, Lemieux C, Dedier H, Wolfaardt G, Gardam MA. 2009. Outbreak of multidrug-resistant Pseudomonas aeruginosa colonization and infection secondary to imperfect intensive care unit room design. Infect. Control Hosp. Epidemiol. 30:25-33.
40. Kodaka H, Iwata M, Yumoto S, Kashitani F. 2003. Evaluation of a new agar medium containing cetrimide, kanamycin and nalidixic acid for isolation and enhancement of pigment production of Pseudomonas aeruginosa in clinical samples. J. Basic Microbiol. 43:407-413.
41. Breathnach AS, Cubbon MD, Karunaharan RN, Pope CF, Planche TD. 2012. Multidrug-resistant Pseudomonas aeruginosa outbreaks in two hospitals: association with contaminated hospital waste-water systems. J. Hosp. Infect. 82:19-24.
42. Hoque SN, Graham J, Kaufmann ME, Tabaqchali S. 2001. Chryseobacterium (Flavobacterium) meningosepticum outbreak associated with colonization of water taps in a neonatal intensive care unit. J. Hosp. Infect. 47:188-192.
43. Regnath T, Kreutzberger M, Illing S, Oehme R, Liesenfeld O. 2004. Prevalence of Pseudomonas aeruginosa in households of patients with cystic fibrosis. Int. J. Hyg. Environ. Health 207:585-588.
44. Schelstraete P, Van Daele S, De Boeck K, Proesmans M, Lebecque P, Leclercq-Foucart J, Malfroot A, Vaneechoutte M, De Baets F. 2008. Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients. Eur. Respir. J. 31:822-829.
45. Reverdy ME, Freney J, Fleurette J, Coulet M, Surgot M, Marmet D, Ploton C. 1984. Nosocomial colonization and infection by Achromobacter xylosoxidans. J. Clin. Microbiol. 19:140-143.
46. Ridderberg W, Bendstrup KE, Olesen HV, Jensen-Fangel S, Norskov-Lauritsen N. 2011. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J. Cyst. Fibros. 10:466-469.